| abstract |
The invention relates to immunotherapy using dendritic cells (DCs). More specifically, it relates to methods for the maturation of DCs, a mature DC population and clinical uses thereof. Provided is a method for the ex vivo maturation of DCs, comprising providing immature DCs and contacting the immature DCs with an effective concentration of a TLR4 agonist, such as Monophosphoryl lipid A (MPLA), and an interferon gamma (IFNγ) receptor agonist, under culture conditions suitable for maturation of the immature DCs to form a mature DC population. Also provided is an isolated population of mature DCs, preferably human mature DCs, and the use thereof in immunotherapy. |